Follistatin: Molecular Structure

Molecular Structure and Properties#

Follistatin is a cysteine-rich glycoprotein that exists in multiple isoforms generated by alternative splicing. The primary structure consists of an N-terminal domain (ND) followed by three follistatin domains (FSD1, FSD2, FSD3), each containing an EGF-like subdomain and a kazal-type serine protease inhibitor subdomain. The protein is heavily disulfide-bonded, with the characteristic follistatin domain structure being stabilized by multiple intradomain disulfide bridges.

Isoform Architecture#

The FST-344 precursor contains a 29-residue acidic C-terminal tail that is proteolytically removed to generate FST-315. This isoform was selected for gene therapy applications (AAV1.CMV.huFS344) because it produces the circulating form with minimal effects on the hypothalamic-pituitary-gonadal axis compared to FST-288, which has greater local tissue activity.

Domain Functions#

The N-terminal domain (ND) is critical for high-affinity activin and myostatin binding. FSD1 and FSD2 contribute to ligand recognition, while FSD3 and the C-terminal tail modulate isoform-specific properties such as heparan sulfate binding and circulating half-life.

Crystal structures of follistatin bound to myostatin (PDB: 3HH2) and activin (PDB: 2B0U) reveal that follistatin encircles the ligand dimer, making extensive contacts that bury the type I and type II receptor binding sites. This structural mechanism explains the essentially irreversible nature of follistatin-mediated ligand neutralization.

Pharmacokinetics#

Circulating FST-315 has a relatively short half-life of approximately 2-4 hours, necessitating frequent dosing if administered as a recombinant protein. This pharmacokinetic limitation has driven the development of gene therapy approaches, which provide sustained local expression from a single administration.

AAV-mediated gene therapy produces persistent transgene expression, with detectable follistatin levels maintained for years after a single intramuscular injection in preclinical models. In human gene therapy trials, the AAV1 vector delivered to quadriceps muscles produced sustained local follistatin expression with functional improvements maintained throughout the study period.

Stability and Storage#

Recombinant follistatin protein is moderately stable when stored at -80 degrees C in lyophilized form. Reconstituted solutions should be stored at 2-8 degrees C and used within a defined timeframe. The protein is susceptible to aggregation at elevated temperatures and should not be subjected to freeze-thaw cycles.

Molecular Context#

Follistatin belongs to the Musculoskeletal category of research peptides. The molecular properties of Follistatin determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.

Structural Overview#

Follistatin is characterized as: Multi-domain glycoprotein with N-terminal domain and three follistatin domains (FSD1-3).

Amino Acid Sequence Details#

The amino acid sequence of Follistatin is: 344 amino acid precursor; mature forms FST-288, FST-303, FST-315. This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.

Pharmacokinetic Profile#

Half-Life: Approximately 2-4 hours (circulating FST-315)

The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.

Related Reading#

• Follistatin overview and research guide
• Peptides similar to Follistatin
• Follistatin research evidence